A Single-center, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Ethoximod in Healthy Subjects.
The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Ethoximod in healthy subjects. The main questions it arms to answer are:
to evaluate the safety and tolerance of Ethoximod in healthy subjects after single or repeated doses.
to assess the pharmacokinetics and pharmacodynamics of Ethoximod in healthy subjects after single or repeated doses.
to evaluate of the effect of food on the pharmacokinetics of Ethoximod in healthy subjects Participants will receive test tablets or placebo at the indicated date and collect blood samples.
A Single-center, Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Proximod in Healthy Subjects and Patients With Rheumatoid Arthritis.
The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects and patients with rheumatoid arthritis. The main questions it arms to answer are:
to evaluate the safety and tolerance of Proximod in health subjects after repeated doses.
to assess the pharmacokinetics and pharmacodynamics of Proximod in healthy subjects after repeated doses.
to evaluate the safety and tolerance of Proximod in patients with rheumatoid arthritis.
to evaluate the pharmacokinetics and pharmacodynamics of Proximod in patients with rheumatoid arthritis.
Participants will receive test tablets or placebo at the indicated date and collect blood samples.
A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Proximod in Healthy Subjects.
The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects. The main questions it arms to answer are:
to evaluate the safety and tolerance of Proximod in healthy subjects after single or repeated doses.
to learn the pharmacodynamics of Proximod in healthy subjects after single or repeated doses.
to evaluation of the effect of food on the pharmacokinetics of Proximod in healthy subjects Participants will receive test tablets or placebo at the indicated date and collect blood samples.
100 项与 Longevity, Inc. 相关的临床结果
0 项与 Longevity, Inc. 相关的专利(医药)
100 项与 Longevity, Inc. 相关的药物交易
100 项与 Longevity, Inc. 相关的转化医学